Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 1.00 |
| ▸ | ACE | P12821 | 3/20 | 1.00 |
| ▸ | MME | P08473 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.51 |
| ▸ | IL1RN | P18510 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidon SCHEMBL17813729 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL9100804 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL4436662 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL117398 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL40933 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL14503212 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL7155564 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL8029985 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL7300320 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| SCHEMBL20179087 | 0.87 | ECE1 (0.78) | ECE1ACEMMELMNAERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122691-A1 | CLEANING COMPOSITIONS | PROCTER & GAMBLE (US) | 2016-05-05 | — | — | US | disclosed |
| US-8541354-B2 | Catalytic laundry detergent composition comprising relatively low levels of water-soluble electrolyte | THE PROCTER & GAMBLE COMPANY (US) | 2013-09-24 | — | — | US | disclosed |
| US-20090209447-A1 | CLEANING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2009-08-20 | — | — | US | disclosed |
| WO-2007025999-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | SERENTIS LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | ECE1 532/4885ACE 713/4885MME 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.